PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT
PREPARED IN ANTICIPATION OF LITIGATION AND IN CONNECTION WITH THE PROVISION OF LEGAL ADVICE — DO NOT DISTRIBUTE WITHOUT PARTNER APPROVAL
CALDERWOOD & HARKNESS LLP 1735 Market Street, Suite 3100 Philadelphia, PA 19103
INTERNAL MEMORANDUM
Matter Number: 1018-00009
Date: March 1, 2024
From: Garrett Simmons, Lead Associate, Tax Department
To: Leonard Cross, Responsible Partner; Sylvia Hartwell, Billing Partner
CC: Leila Nazari, Working Associate
Re: Summary of IRS Appeals Conference — Penterra Pharmaceuticals Corp. (EIN 22-3741856), Tax Years 2017–2020, IRS Exam Team ID LB&I-NE-TP-2022-00641
I. Purpose and Overview
The purpose of this memorandum is to provide a contemporaneous summary of the in-person IRS Appeals conference held on Wednesday, February 28, 2024, at the IRS Appeals Office in Manhattan, New York, concerning the transfer pricing examination of Penterra Pharmaceuticals Corp. ("PPC") for tax years 2017, 2018, 2019, and 2020. This memorandum is prepared as attorney work product in anticipation of litigation and in connection with Calderwood & Harkness LLP's ("C&H") provision of legal advice to PPC.
The conference addressed PPC's Formal Protest filed on December 22, 2023, which contested the $380.4 million net proposed adjustment set forth in the Notice of Proposed Adjustment ("NOPA") dated October 12, 2023. As detailed in the Protest and summarized more fully below, the NOPA included the following components:
• Cost-sharing arrangement ("CSA") cost-sharing ratio adjustments totaling $235.01 million across the four examination years;
• Legacy intellectual property royalty rate adjustments totaling $188.04 million across the four examination years;
• A correlative offset of ($42.65 million) to eliminate double-counting between the CSA and royalty adjustments; and
• A proposed penalty under IRC § 6662(e) for substantial valuation misstatement of approximately $15.98 million.
The conference was the first substantive meeting between PPC's representatives and the assigned Appeals Officer since the matter was referred to IRS Appeals. This memorandum summarizes the presentation made by the C&H and PPC team, the questions and reactions of the Appeals Officer, and our assessment of the settlement trajectory based on the day's proceedings.
Overall Assessment: Appeals Officer Noreen Castañeda appeared receptive to significant elements of PPC's defense, particularly with respect to PBI's economic substance, the DEMPE functions analysis, and the penalty protection arguments. The conference proceeded in a constructive and professional manner throughout the day. Castañeda was well-prepared and asked probing questions, but her reactions suggested that the IRS exam team's proposed adjustments were, in her view, aggressive in several respects. Based on the totality of her questions, comments, and demeanor, a settlement trajectory in the range of 10%–15% of the proposed $380.4 million net adjustment appears achievable, which would fall within the settlement authority parameters established in the December 10, 2023 Settlement Authority Memorandum.
II. Conference Logistics
A. Date, Time, and Location
The conference was held on Wednesday, February 28, 2024, commencing at 10:00 a.m. and concluding at approximately 4:15 p.m. (Eastern Time). A lunch break was taken from approximately 12:30 p.m. to 1:30 p.m., during which the PPC team conferred privately in a separate conference room. The total substantive session time was approximately five hours and fifteen minutes.
The conference was held at the IRS Appeals Office, Manhattan, New York. The meeting took place in a standard IRS conference room. Appeals Officer Castañeda had arranged for the room in advance, and the physical setup accommodated the six-member PPC/C&H team and Castañeda without difficulty.
B. Attendees
The following individuals were present at the conference:
PPC / Calderwood & Harkness LLP Team:
IRS Appeals:
Not Present (IRS Examination Team):
The following members of the IRS examination team were not present at the conference: Supervisory Revenue Agent Gerald Meskill, Lead Revenue Agent Patricia Dunleavy, IRS Economist Dr. Alan Washburne, and Attorney-Advisor Franklin Rosario. At the outset of the conference, Appeals Officer Castañeda confirmed that she had conferred with the examination team and IRS Chief Counsel prior to the conference to familiarize herself with the case, but she emphasized that the February 28 session was conducted as an ex parte-free session with the taxpayer, consistent with Rev. Proc. 2012-18 and IRS Appeals' independence protocols. The examination team was not consulted during the conference, and Castañeda made clear that she would exercise independent settlement authority.
C. Format
The conference followed a presentation-and-dialogue format. Leonard Cross delivered the primary presentation on behalf of PPC, utilizing the Northgate Services Inc. presentation that had been prepared specifically for the conference by the C&H team. The presentation was organized by issue and tracked the structure of the Formal Protest. Dr. Helena Vasquez of Whitmore Valuation Group LLC presented the economic analysis sections of the presentation, including the CUT analysis, CPM/TNMM benchmarking, and DCF valuation of the platform contribution transaction ("PCT"). Marcus Whitfield provided factual context regarding PBI's operations, headcount, governance, and commercial activities, particularly during the economic substance and DEMPE portions of the discussion.
Appeals Officer Castañeda interspersed questions throughout the presentation rather than reserving all questions for the end. This interactive format was productive, as it allowed PPC's team to address Castañeda's concerns in real time and to tailor the depth of the presentation to issues of greatest interest to the Appeals Officer. In addition, Castañeda reserved a period of approximately 45 minutes at the conclusion of the presentation (from approximately 3:30 p.m. to 4:15 p.m.) for her own follow-up questions, which covered several topics across multiple issues.
At the outset of the conference, C&H provided Appeals Officer Castañeda with a comprehensive document binder containing the Formal Protest, all five exhibits (Exhibits A through E), the Whitmore Valuation Group economic analyses (CUT analysis, CPM/TNMM benchmarking report, and DCF/income method PCT valuation report), evidence of PBI's economic substance, and summaries of legal authorities and relevant case law. A hard copy of the Northgate Services Inc. presentation was also provided. A full index of the materials provided to Appeals is set forth in Section X of this memorandum.
III. Summary of Presentation and Discussion by Issue
A. Opening Remarks and Case Overview
Cross opened the conference by thanking Appeals Officer Castañeda for scheduling the in-person session and for her thorough preparation. Cross then provided an overview of PPC's corporate structure, which was essential context for the transfer pricing issues under examination.
Corporate Structure. PPC is a Delaware corporation publicly traded on the Nasdaq Stock Market under the ticker symbol "PPCA," with its global headquarters at 2200 Independence Boulevard, Princeton Junction, New Jersey. PPC is the U.S. parent of a global pharmaceutical group. The relevant entities in the transfer pricing structure are as follows:
• Penterra Pharmaceuticals Corp. ("PPC") — U.S. parent, Delaware corporation, Nasdaq-listed, headquartered in Princeton Junction, NJ. PPC conducts R&D and commercializes pharmaceutical products in the Americas region.
• Penterra Holdings Luxembourg S.à r.l. ("PHL") — Luxembourg holding entity, wholly owned by PPC. PHL is treated as a disregarded entity for U.S. federal income tax purposes under Treas. Reg. § 301.7701-3.
• Penterra Biopharma International DAC ("PBI") — Irish designated activity company, wholly owned by PHL, registered at Sandyford Business Park, Dublin, Ireland. PBI serves as the IP-holding company and principal for non-Americas commercialization activities. PBI is a controlled participant in the CSA with PPC.
• Penterra Manufacturing Ireland Ltd. ("PMI") — Irish limited company, wholly owned by PBI, with manufacturing facilities in County Cork, Ireland. PMI operates as a contract manufacturer for PBI on a cost-plus-8% basis.
CSA and Legacy IP Arrangements. Cross summarized the two primary intercompany arrangements at issue:
1. Cost-Sharing Arrangement (effective July 1, 2012): PPC and PBI entered into a qualified cost-sharing arrangement under Treas. Reg. § 1.482-7, pursuant to which the parties share the costs and risks of ongoing R&D activities in exchange for the right to exploit resulting intangible property in their respective territories (Americas for PPC; non-Americas for PBI). At the inception of the CSA, PBI made a platform contribution transaction ("PCT") payment of $312 million to PPC, compensating PPC for the pre-existing intangible property made available to PBI under the arrangement.
2. Legacy IP Royalty Arrangement: For legacy pharmaceutical compounds (i.e., products that predated the CSA and were not subject to the cost-sharing arrangement), PBI pays PPC a royalty of 4.5% of net sales in non-Americas territories. These legacy compounds are in the declining phase of their product lifecycles.
Contemporaneous Documentation. Cross emphasized that PPC maintained contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP ("Crestfield") for all four examination tax years (2017, 2018, 2019, and 2020). This documentation was prepared in compliance with the requirements of Treas. Reg. § 1.482-7 (for the CSA) and Treas. Reg. § 1.482-4 (for the royalty arrangement), and was completed prior to the applicable return filing deadlines in each year. The documentation included benchmarking studies, economic analyses, and detailed descriptions of the methodologies applied.
Castañeda's Reaction. Appeals Officer Castañeda acknowledged receipt and thorough review of the Formal Protest and all supporting exhibits. She indicated that she had reviewed the complete case file, including the examination team's Revenue Agent Report ("RAR"), Dr. Washburne's economic analysis prepared for the IRS, and the NOPA itself. Castañeda stated that she approached the case with a "fresh look" consistent with Appeals' mandate to exercise independent settlement authority, and she confirmed her understanding that the purpose of the conference was to hear the taxpayer's position and to explore the possibility of a mutually acceptable resolution. She expressed no preliminary views on the merits at this stage, reserving her questions for the issue-by-issue discussion that followed.
B. Issue 1: CSA Cost-Sharing Ratio ($235.01M Proposed Adjustment)
1. PPC's Position as Presented
Cross presented PPC's position on the CSA cost-sharing ratio, which constitutes the largest single component of the proposed adjustment. PPC's cost-sharing percentages for the four examination years were as follows:
These percentages were determined based on reasonably anticipated benefits ("RAB") under Treas. Reg. § 1.482-7, reflecting PBI's projected share of the benefits from intangible development activities relative to PPC's projected share. The gradual increase in PBI's share from 38.2% to 42.7% over the four-year period reflected PBI's expanding non-Americas market presence and growing projected revenue streams.
Total qualified R&D costs subject to cost-sharing and PBI's allocated shares were as follows:
PPC's RAB methodology was based on projected revenue splits between Americas and non-Americas territories, supported by detailed product-level revenue projections for each of PPC's key pharmaceutical products. Cross and Dr. Vasquez presented the product-level data, which included projections for the following major products:
• Veritaxol (oncology): 2020 global revenue of $3.12 billion, of which $1.34 billion (43.0%) was attributable to non-Americas territories.
• Imvara (immunology): 2020 global revenue of $1.87 billion, of which $0.79 billion (42.2%) was attributable to non-Americas territories.
• Cerulon (rare disease): 2020 global revenue of $0.62 billion, of which $0.28 billion (45.2%) was attributable to non-Americas territories.
Dr. Vasquez then presented the CPM/TNMM (comparable profits method / transactional net margin method) analysis prepared by Whitmore Valuation Group, which tested PBI's operating margins against a set of 22 comparable distributors and IP-holding companies identified through a rigorous search process using standard commercial databases. PBI's operating margins fell within the interquartile range of the comparable set in all four examination years, confirming that PBI's reported results were consistent with arm's-length outcomes.
Cross argued that the IRS examination team's proposed increases of 8–12 percentage points in PBI's cost-sharing ratio — resulting in proposed cost-sharing percentages of 48.2% (2017), 50.6% (2018), 52.3% (2019), and 53.7% (2020) — were unsupported by any defensible RAB methodology. Cross contended that the examination team had failed to articulate a coherent basis for these elevated percentages and that the proposed adjustments appeared to be driven by a results-oriented approach rather than a principled application of the RAB framework under the regulations.
2. IRS Position (as Reflected in NOPA / Exam File)
The IRS examination team asserted that PPC's RAB projections understated the value attributable to U.S.-source contributions and that the cost-sharing ratio should have been higher to reflect the concentration of PPC's R&D workforce and facilities in the United States. The examination team's position was that PPC's projected non-Americas revenues were overstated relative to the actual contributions of the U.S.-based R&D enterprise, and that PBI's share of costs should therefore have been higher to compensate PPC for the disproportionate U.S.-based contribution to intangible development.
The resulting proposed additional cost-sharing payments from PBI to PPC were as follows:
3. Appeals Officer Castañeda's Questions and Reactions
Appeals Officer Castañeda devoted substantial attention to the CSA cost-sharing ratio issue. She asked detailed and well-informed questions about how PPC determined the RAB split, focusing on three specific areas:
(a) Revenue Metric. Castañeda asked which revenue metric was used in the RAB calculation — specifically, whether PPC used gross sales or net sales. Cross and Dr. Vasquez confirmed that PPC used net sales as the revenue metric, consistent with the provisions of Treas. Reg. § 1.482-7(e)(2)(ii). Dr. Vasquez explained that the use of net sales was the standard approach for RAB calculations in the pharmaceutical industry and was consistent with the treatment in PPC's contemporaneous transfer pricing documentation.
(b) New Product Launch Projections. Castañeda asked how new product launches in non-Americas territories were projected and factored into the RAB analysis. This was a focused question, as the timing and magnitude of product launches in non-Americas markets directly affect PBI's projected share of benefits. Dr. Vasquez explained that PPC's RAB projections for new product launches were based on detailed market-by-market analyses, incorporating expected regulatory approval timelines, market access and pricing assumptions, and projected uptake curves based on comparable product launches in each territory. These projections were prepared contemporaneously with the cost-sharing calculations for each tax year and were documented in the Crestfield transfer pricing reports.
(c) Retrospective Testing. Castañeda asked whether PPC had retrospectively tested its RAB projections against actual revenue results for the examination years. This was a significant question, as a material divergence between projected and actual results could undermine the reliability of the RAB methodology. Dr. Vasquez responded that PPC had conducted retrospective testing and that the projections were within reasonable bounds of actual results. Specifically, the variance between projected and actual non-Americas revenue shares was within a range of approximately 1.5–3.0 percentage points across the four examination years, which Vasquez characterized as reasonable given the inherent uncertainty in long-term pharmaceutical revenue projections. Vasquez noted that such variance was well within the range that would be expected from comparable companies making similar projections.
Beyond these specific questions, Castañeda expressed notable skepticism about the IRS examination team's proposed percentages. She stated that she had "difficulty reconciling" the examination team's 8–12 percentage point upward adjustments with the comparable data presented by Whitmore Valuation Group. She noted that the examination team's RAB analysis appeared to underweight PBI's marketing and regulatory contributions in non-Americas markets, and she questioned whether the examination team had adequately accounted for the economic value of PBI's activities in the DEMPE framework when computing the RAB split.
Castañeda also raised an insightful question about the impact of the Tax Cuts and Jobs Act ("TCJA"), which became effective on January 1, 2018, and reduced the U.S. corporate tax rate from 35% to 21%. Castañeda asked whether the TCJA rate change altered the economic incentives underlying the CSA, and whether the cost-sharing percentages should have been adjusted to reflect the changed tax landscape. Cross responded that the cost-sharing percentages were driven by RAB projections — that is, by projected economic benefits — and not by tax rate differentials. He emphasized that the RAB methodology remained constant across all four examination years and that the cost-sharing percentages were a function of projected arm's-length economic outcomes, not of tax arbitrage. Cross noted that while the TCJA obviously changed the after-tax benefit of the arrangement, the Treas. Reg. § 1.482-7 framework does not call for tax-rate-adjusted RAB calculations. Castañeda appeared to accept this explanation without further pressing the point.
Assessment: Castañeda appeared to view the examination team's CSA adjustment as the weaker of the two primary adjustments (the other being the royalty rate adjustment). She did not seem persuaded that a 10–12 percentage point increase in PBI's cost-sharing ratio was warranted. Her questions suggested that she recognized PPC's RAB methodology was sound and that the comparable data supported PPC's cost-sharing percentages. However, she stopped short of conceding the issue entirely, and her questions about new product launch projections and retrospective testing suggest she may be considering whether a more modest upward adjustment (significantly less than the examination team's proposed 8–12 percentage points) could be justified. Overall, we believe Castañeda may be prepared to concede significant ground on this issue in settlement negotiations.
C. Issue 2: Legacy IP Royalty Rate ($188.04M Proposed Adjustment)
1. PPC's Position as Presented
Cross presented PPC's position on the legacy IP royalty rate, which is the second-largest component of the proposed adjustment. PPC charges PBI a royalty of 4.5% of net sales on legacy pharmaceutical compounds sold in non-Americas territories. These legacy compounds — products that predated the July 2012 CSA and are not subject to the cost-sharing arrangement — are in the declining phase of their product lifecycles, with net sales in non-Americas territories declining steadily over the examination period:
Dr. Vasquez presented the comparable uncontrolled transaction ("CUT") analysis prepared by Whitmore Valuation Group, which formed the primary basis for PPC's arm's-length royalty rate determination. The CUT analysis identified 14 comparable uncontrolled pharmaceutical license agreements through a systematic search of publicly available license agreement databases and other sources. The search criteria focused on agreements involving mature pharmaceutical compounds with declining lifecycle profiles, comparable therapeutic areas, and similar geographic scope. The results of the CUT analysis were as follows:
• Interquartile range of royalty rates: 3.1% – 6.8%
• Median royalty rate: 4.4%
• PPC's applied rate: 4.5%
PPC's 4.5% royalty rate fell squarely within the arm's-length range and was almost exactly at the median of the comparable set. Dr. Vasquez emphasized that the CUT method was the best method under Treas. Reg. § 1.482-4(c) for testing the royalty rate, given the availability of sufficiently comparable uncontrolled agreements, and that the quality and quantity of comparable data made this analysis highly reliable.
Cross argued that the IRS's proposed 11.0% royalty rate was outside the arm's-length range established by PPC's CUT analysis and was based on the IRS examination team's selection of non-comparable license agreements. Specifically, Cross contended that the IRS's selected CUT comparables involved blockbuster pharmaceutical compounds with significantly different risk profiles, therapeutic areas, and remaining patent life compared to PPC's mature, declining legacy compounds. The IRS's comparable set was therefore not reflective of arm's-length pricing for compounds in PPC's specific commercial and lifecycle position.
2. IRS Position (as Reflected in NOPA / Exam File)
The IRS examination team proposed increasing the royalty rate from 4.5% to 11.0%, based on the IRS's own CUT analysis, which selected a different set of comparable license agreements. The IRS's comparable set included agreements that, in PPC's view, were not sufficiently comparable to the legacy IP license at issue. The resulting proposed additional royalty payments from PBI to PPC were as follows:
3. Appeals Officer Castañeda's Questions and Reactions
Castañeda devoted significant time to the CUT analysis, which appeared to be the issue of greatest analytical interest to her. She asked Dr. Vasquez to walk through the comparable selection criteria in detail, including the search methodology, the databases used, and the specific adjustments (if any) made to the comparable data.
Castañeda's key questions focused on the following areas:
(a) Exclusion of IRS-Selected Comparables. Castañeda asked why certain license agreements selected by the IRS examination team as comparables were excluded from Whitmore's analysis. Dr. Vasquez explained that the exclusion criteria were based on well-established comparability standards under Treas. Reg. § 1.482-4(c). Specifically, the IRS's selected CUTs included agreements for early-stage pipeline compounds with significant remaining patent life and substantial upside potential. These agreements were fundamentally different from PPC's legacy compound licenses, which involved mature products in a declining lifecycle with limited or no remaining patent protection and diminishing market exclusivity. Several of the IRS's selected comparables also involved different therapeutic categories (e.g., central nervous system and cardiovascular compounds) and different geographic scopes (e.g., single-country licenses versus PBI's broad non-Americas geographic scope). Vasquez emphasized that including such non-comparable agreements would have distorted the arm's-length range.
(b) Declining Lifecycle of Legacy Compounds. Castañeda asked whether the legacy compounds were truly in a declining lifecycle and, if so, how that fact affected comparability. This was a substantive question directed at the core of the CUT analysis, since the declining trajectory of the legacy compounds was a key factor in PPC's comparable selection. Vasquez confirmed that the legacy compounds were indeed experiencing year-over-year revenue declines attributable to generic competition, patent expirations, and the natural maturation of the products in their respective markets. Vasquez explained that the declining lifecycle was a critical comparability factor, as license agreements for declining-lifecycle compounds typically command lower royalty rates than agreements for growth-stage or blockbuster compounds, reflecting the lower risk-adjusted economic value of the licensed IP.
(c) Therapeutic-Area Composition. Castañeda asked whether any of the 14 CUT comparables involved oncology compounds specifically, given that Veritaxol (PPC's largest product) is an oncology compound. While the CUT analysis related to the legacy compound royalty (not the CSA-covered products like Veritaxol), the question suggested Castañeda was probing the overall robustness and representativeness of the comparable set. Dr. Vasquez confirmed that 3 of the 14 comparables involved oncology compounds and that the therapeutic-area composition of the comparable set was broadly representative of the legacy compound portfolio, which spanned multiple therapeutic categories.
Castañeda made several notable comments during the CUT analysis discussion. She observed that the IRS's proposed 11.0% royalty rate was "well above" the interquartile range of the taxpayer's comparable set and asked Cross whether there was any basis for applying a royalty rate at the upper end of PPC's IQR (i.e., closer to 6.8%) rather than at the median. This question was significant because it suggested that Castañeda was already looking past the IRS's proposed 11.0% rate and toward a potential settlement position somewhere within PPC's IQR. Cross responded by citing the best method rule under Treas. Reg. § 1.482-1(d), which provides that when the tested party's result falls within the arm's-length range, no adjustment is warranted. Cross argued that the median is the most reliable point estimate of the arm's-length result when the tested party's rate is already within the IQR, and that an adjustment to the upper end of the IQR would not be supported by the data or the regulatory framework. Cross acknowledged, however, that in practice, settlement discussions often involve consideration of where within the IQR the appropriate result might fall.
Castañeda also asked about the declining revenue trajectory of the legacy compounds and whether that trend was expected to continue beyond the examination years. Whitfield confirmed the trajectory, noting that several of PPC's legacy compounds had already lost patent protection in key non-Americas markets and that generic competition was expected to continue eroding revenues. Whitfield also emphasized that PBI bore the market risk for this revenue decline, including pricing pressure, loss of market share to generic competitors, and the regulatory burdens associated with maintaining marketing authorizations in non-Americas markets.
Assessment: Castañeda appeared to find PPC's CUT analysis significantly more credible than the IRS examination team's analysis. She did not express any support for the IRS's proposed 11.0% royalty rate, and her characterization of that rate as "well above" the PPC IQR was telling. However, her question about whether a rate at the upper end of PPC's IQR might be appropriate suggests that she is considering whether a modest upward adjustment from 4.5% (e.g., toward the upper quartile of 6.8%) might be appropriate as a settlement position. Based on the tenor of her questions and comments, we believe a settlement rate in the range of 5.0%–6.0% is plausible on this issue. While any upward adjustment from 4.5% would represent a concession by PPC, such a settlement would be dramatically more favorable than the IRS's proposed 11.0% rate and would remain within the arm's-length range established by PPC's CUT analysis.
D. Issue 3: PCT Valuation ($312M Payment vs. IRS's $852M Valuation)
1. Discussion. Cross noted at the outset of the PCT discussion that tax year 2012 — the year in which the $312 million PCT payment was made — was outside the examination years (2017–2020). The IRS examination team did not propose a separate adjustment to the PCT payment itself. However, the IRS used the alleged undervaluation of the PCT to support its proposed adjustments to the ongoing CSA cost-sharing ratios and royalty rates for 2017–2020, arguing that the purported undervaluation of pre-existing intangible property at the CSA's inception reflected a pattern of under-pricing intercompany transactions between PPC and PBI.
Dr. Vasquez presented the Whitmore DCF/income method analysis of the PCT payment. Using a weighted average cost of capital ("WACC") of 9.8%, the Whitmore analysis determined that the arm's-length range for the PCT payment was $278 million to $361 million, with PPC's actual $312 million payment falling well within that range. By contrast, the IRS examination team, using a WACC of 7.2%, had arrived at a significantly higher valuation of $852 million for the pre-existing intangible property transferred under the PCT.
Dr. Vasquez explained that the 260-basis-point difference between the 7.2% and 9.8% discount rates was the primary driver of the $540 million gap between the IRS and PPC valuations. Given the long-dated nature of the projected cash flows and the compounding effect of the discount rate over a multi-decade projection period, even modest differences in the WACC produced dramatically different present value calculations.
Vasquez provided a detailed explanation of why a 9.8% WACC was the appropriate rate for discounting the projected cash flows from the PCT intangible property:
• Pharmaceutical-industry risk premiums: The pharmaceutical industry is characterized by elevated risk profiles relative to the broader market, due to factors including regulatory risk, clinical trial failure rates, patent cliff exposure, and reimbursement uncertainty. These industry-specific risks warranted a risk premium above what the IRS's lower discount rate implied.
• Beta of comparable specialty pharmaceutical companies: The equity beta used in the WACC calculation was derived from a set of publicly traded specialty pharmaceutical companies comparable to PPC, reflecting the systematic risk associated with pharmaceutical intangible property. The resulting cost of equity was higher than the rate implied by the IRS's analysis.
• Clinical-stage compound uncertainty: At the time of the 2012 CSA inception, several of the compounds included in the PCT were in clinical-stage development, with significant uncertainty regarding their ultimate commercial success. The appropriate discount rate for projections involving such compounds must reflect this uncertainty through a higher risk-adjusted rate.
The difference between the two discount rates, Vasquez emphasized, was not a matter of professional disagreement on a marginal assumption but rather a fundamental divergence in how risk was assessed and priced. Vasquez contended that the IRS's 7.2% WACC materially understated the risk profile of the intangible property and resulted in an inflated valuation that did not reflect arm's-length conditions.
2. Appeals Officer Castañeda's Questions and Reactions
Castañeda asked pointed questions about the discount rate dispute, which she clearly understood to be the central valuation issue. She requested that Dr. Vasquez walk through the specific components of the WACC calculation, including the risk-free rate, equity risk premium, size premium, company-specific risk premium, beta, cost of debt, and capital structure assumptions. Vasquez provided this walkthrough, and Castañeda followed along with apparent familiarity, suggesting she had reviewed valuation methodology prior to the conference.
Castañeda asked whether PPC could provide any additional support for the risk-premium assumptions, including any post-2012 evidence of pharmaceutical IP valuations that might corroborate the appropriateness of the 9.8% WACC. This was a forward-looking question that appeared to be probing whether there was additional data that might strengthen PPC's position or, alternatively, undermine it. Dr. Vasquez responded that post-2012 comparable pharmaceutical IP transactions supported the use of a higher discount rate, and that several published studies on pharmaceutical IP valuation had confirmed that discount rates in the range of 9%–12% were common for pharmaceutical intangible property of the type included in the PCT. Vasquez indicated that she could provide additional supporting data if requested.
Castañeda did not express a strong opinion on the PCT valuation itself. She acknowledged that the PCT payment was made in a year outside the examination period and noted that the PCT valuation was "relevant as background to the cost-sharing ratio analysis" for the examination years. However, she did not indicate that the PCT valuation issue would independently drive a large adjustment for 2017–2020. Her questions were probing but not adversarial, and she appeared to treat the PCT issue as secondary to the direct CSA and royalty rate questions.
Assessment: The PCT valuation appeared to be a secondary issue for Castañeda, consistent with the fact that the PCT payment year (2012) is outside the examination period. She seemed more focused on the direct CSA cost-sharing ratio and legacy IP royalty rate adjustments for 2017–2020. While the PCT valuation may factor into Castañeda's overall assessment of the intercompany pricing landscape, we do not expect it to be a significant driver of the settlement outcome. Castañeda's questions about additional supporting data suggest she may want additional confirmation of the discount rate assumptions before finalizing her analysis, which is addressed in the supplemental submission discussed in Section VIII below.
E. Issue 4: PBI Economic Substance and DEMPE Functions
1. PPC's Position as Presented
Cross and Whitfield presented a comprehensive package of evidence demonstrating PBI's economic substance and its meaningful performance of DEMPE functions (Development, Enhancement, Maintenance, Protection, and Exploitation of intangible property). This issue was foundational to PPC's defense, as the IRS examination team's adjustments implicitly rested on the premise that PBI lacked sufficient substance to justify its role as IP owner and principal for non-Americas commercialization.
The evidence presented included the following:
Personnel and Headcount:
• PBI employed 185 employees in Dublin as of year-end 2020, having grown from 52 employees at the time of its incorporation in March 2012. This headcount growth reflected PBI's expanding commercial operations and its increasing role as the operational principal for non-Americas markets.
Governance and Board Activity:
• PBI held 42 board meetings in Dublin during the 2017–2020 examination period, consisting of regular quarterly meetings plus special sessions convened as needed. These board meetings were held in Dublin, attended by PBI's directors, and addressed substantive matters including strategic planning, budget approval, product launch decisions, pricing strategies, and regulatory submissions.
Regulatory Expenditures:
• PBI incurred €47.2 million in cumulative regulatory expenditures during 2017–2020, covering marketing authorization submissions, variations, renewals, and post-marketing commitments across 68 country markets in the non-Americas territories.
Physical Presence:
• PBI occupied approximately 18,000 square feet of office space at Sandyford Business Park, Dublin, which served as the operational headquarters for the non-Americas business.
Commercial Decision-Making:
• PBI made independent pricing decisions across 68 non-Americas country markets, tailored to local market conditions, reimbursement environments, and competitive dynamics. PBI's commercial team was responsible for market entry decisions, distribution partner selection, tender submissions, key account management, and strategic commercial planning.
Risk Bearing:
• PBI bore market risk for non-Americas territories, including the risk of revenue decline from generic competition, pricing pressure, adverse regulatory actions, and market access challenges. PBI's financial results reflected these risks, with fluctuations in profitability that correlated with market-specific events.
Management and Leadership:
• Managing Director Aidan Naughton had been in place since PBI's inception and oversaw a growing team of regulatory, medical-affairs, commercial-strategy, and supply-chain personnel. Naughton was based in Dublin and reported to PBI's independent board of directors.
Banking and Financial Independence:
• PBI maintained independent banking relationships with Glenmore Bank Ireland plc, including operating accounts, treasury functions, and working capital management.
Cross then presented the DEMPE functions matrix (Protest Exhibit D), which systematically documented PBI's contributions across all five DEMPE categories:
• Development: PBI participated in intangible development through the CSA, sharing costs and risks of ongoing R&D activities.
• Enhancement: PBI conducted local regulatory and clinical activities that enhanced the value of intangible property in non-Americas markets, including Phase IV clinical trials, real-world evidence studies, and label expansion submissions.
• Maintenance: PBI engaged in ongoing IP management in non-Americas jurisdictions, including maintenance of marketing authorizations, pharmacovigilance, and regulatory compliance.
• Protection: PBI managed local trademark and patent protection in non-Americas markets, coordinating with outside counsel in relevant jurisdictions.
• Exploitation: PBI exercised full commercial decision-making authority over the exploitation of intangible property in non-Americas territories, including pricing, marketing, distribution, and market access strategies.
Cross also highlighted the 12 PBI employee interviews conducted by Simmons and Nazari during August–September 2022, which documented the functional roles, decision-making authority, and day-to-day responsibilities of key PBI personnel across multiple departments (regulatory, medical affairs, commercial strategy, supply chain, finance, and legal). These interviews provided direct, first-hand evidence of the substance and operational independence of the PBI organization.
Cross concluded the economic substance presentation by arguing that the IRS examination team's implicit economic substance challenge failed because PBI was not a shell entity but rather maintained genuine operational capabilities, a significant and growing workforce, independent decision-making authority, and real economic risk in its Dublin operations.
2. Appeals Officer Castañeda's Questions and Reactions
Castañeda asked several probing but ultimately favorable questions on the economic substance issue:
Dual Employment / Reporting Relationships. Castañeda asked whether any of PBI's 185 employees had dual employment arrangements or reporting relationships with PPC in the United States. This was a common question in transfer pricing examinations involving intercompany IP structures, as dual employment or dotted-line reporting to U.S. management could undermine the claim of PBI's operational independence. Whitfield confirmed that PBI employees reported to PBI management exclusively, with Managing Director Naughton reporting to PBI's independent board of directors. There were no dual employment arrangements, and PBI employees were hired, compensated, evaluated, and managed entirely within the PBI organization in Dublin.
Headcount Proportionality. Castañeda asked about the ratio of PBI's headcount (185 employees) to PPC's global headcount (approximately 14,500 employees) and whether the Dublin operations could genuinely manage non-Americas commercialization with that level of staffing. This was a substantive question that went to the heart of whether PBI's operations were proportionate to its claimed role as principal for non-Americas activities. Cross responded that PBI's role was as a principal, not as a full-service operating company. PBI utilized contract manufacturing through PMI (which employed 620 employees at its Cork facility and operated on a cost-plus-8% basis) and engaged third-party distribution partners in non-Americas markets to perform local sales and distribution functions. This business model — in which the principal entity maintains a lean headquarters staff and outsources manufacturing and local distribution to contract parties — is a normal and well-established business model for pharmaceutical IP-holding and commercialization entities. The 185-employee headcount at PBI was concentrated in the functions that an IP-holding and commercialization principal would be expected to perform: regulatory affairs, medical affairs, commercial strategy, supply chain management, finance, and legal.
Capital Expenditures and Fixed Assets. Castañeda asked about PBI's capital expenditures beyond the regulatory spend documented in the presentation and whether PBI had significant fixed assets. Whitfield described PBI's investments in IT infrastructure (including ERP systems, regulatory submission platforms, and commercial analytics tools), office buildout at the Sandyford Business Park facility, and equipment investments for quality assurance and regulatory compliance functions. While PBI's fixed asset base was not as large as that of a manufacturing entity, this was consistent with its role as an IP-holding and commercialization principal.
Assessment: Castañeda appeared largely persuaded on the economic substance point. Her questions were thorough but did not suggest fundamental skepticism about PBI's operational reality. She did not seem inclined to pursue the DEMPE/economic substance challenge as an independent basis for adjustment. However, she noted that "the substance of the entity is relevant context for the pricing issues," suggesting that she views PBI's substance as a factor that informs but does not independently resolve the transfer pricing questions. Overall, we believe the economic substance issue is unlikely to be a significant factor in the settlement, and that Castañeda's assessment of PBI's substance will, if anything, support PPC's position on the CSA and royalty rate issues.
F. Issue 5: IRC § 6662(e) Penalty ($15.98M Proposed)
1. PPC's Position as Presented
Cross presented PPC's defense against the proposed IRC § 6662(e) substantial valuation misstatement penalty of approximately $15.98 million. PPC's defense rested on two principal grounds:
Reasonable-Cause Defense. Under IRC § 6662(e)(3)(B), a taxpayer may avoid the substantial valuation misstatement penalty by demonstrating reasonable cause for, and good faith with respect to, the transfer pricing position taken on its return. Cross argued that PPC satisfied this standard because it relied on the advice and work product of qualified professionals — specifically, Crestfield & Associates LLP for transfer pricing documentation and Whitmore Valuation Group LLC for economic analysis and valuation — and applied recognized transfer pricing methods (CUT, CPM/TNMM, and income method/DCF) in determining its intercompany pricing.
Contemporaneous Documentation. PPC maintained contemporaneous transfer pricing documentation prepared by Crestfield & Associates for all four examination tax years (2017, 2018, 2019, and 2020). This documentation was prepared before the return filing deadline for each year and fully addressed the CSA cost-sharing methodology, the royalty rate determination, and the supporting economic analyses. The documentation established that PPC had a principled basis for its transfer pricing positions and had documented that basis contemporaneously with the filing of its returns.
Cross emphasized that even if some adjustments to PPC's transfer pricing were ultimately warranted — which PPC contested — the penalty was not appropriate because PPC's positions were taken in good faith, supported by qualified professional advice, documented contemporaneously, and based on recognized transfer pricing methods that produced results within or very near the arm's-length range. The penalty provisions of IRC § 6662(e) are not intended to punish taxpayers who make good-faith efforts to comply with the transfer pricing rules, and PPC's compliance posture demonstrated exactly the kind of diligence that the reasonable-cause exception was designed to reward.
2. Appeals Officer Castañeda's Questions and Reactions
Castañeda asked two focused questions on the penalty issue:
Timing of Documentation. Castañeda asked whether the contemporaneous documentation was prepared before or after the return filing deadline for each examination year. This was a critical threshold question, as the reasonable-cause defense under IRC § 6662(e)(3)(B) requires that the taxpayer maintain contemporaneous documentation of its transfer pricing methodology. Cross confirmed that the Crestfield documentation was completed prior to the applicable return filing deadline for each of the four examination years, and that the documentation was available for review at the time the returns were filed.
Coverage of NOPA Issues. Castañeda asked whether PPC's contemporaneous documentation specifically addressed the issues raised in the NOPA — namely, the royalty rate and cost-sharing percentages. Cross confirmed that the documentation addressed both issues, with benchmarking studies and economic analyses specifically supporting the positions taken on the CSA cost-sharing ratios and the legacy IP royalty rate. The documentation was not generic or boilerplate but was tailored to PPC's specific intercompany transactions and included the supporting data and analysis required by the regulations.
After receiving Cross's responses, Castañeda stated that she was "inclined to not sustain the penalty" given the quality and timeliness of PPC's contemporaneous documentation, the engagement of qualified professionals, and the fact that PPC's positions fell within or near established arm's-length ranges. This was the most definitive statement Castañeda made on any issue during the conference, and it clearly signaled her intention to abate the penalty in any settlement.
Assessment: Castañeda's comments on the penalty issue were the most favorable of the entire conference on any issue. Her statement that she was "inclined to not sustain the penalty" provides a strong indication that the penalty will be fully abated in any settlement. This is a significant outcome for PPC, as the proposed $15.98 million penalty represented a material component of the overall proposed assessment. Full abatement of the penalty was one of PPC's primary objectives for the conference, and it appears that this objective has been achieved.
IV. Correlative Offset and Interaction of Adjustments
During the presentation, Cross addressed the $42.65 million correlative offset that the IRS examination team had allowed in the NOPA to avoid double-counting between the CSA cost-sharing ratio adjustment and the legacy IP royalty rate adjustment. Because both adjustments relate to payments between PPC and PBI — the CSA adjustment increases PBI's cost-sharing payments to PPC, while the royalty rate adjustment increases PBI's royalty payments to PPC — there is an inherent overlap that must be addressed through correlative adjustments to avoid a duplicative economic effect.
Cross argued that the offset methodology employed by the examination team was insufficient and that a proper application of the correlative adjustment principles under Treas. Reg. § 1.482-1(g) would result in a greater reduction to the net proposed adjustment. Specifically, Cross contended that the examination team had not fully accounted for the interaction between the two adjustments when computing PBI's overall intercompany payments to PPC, and that a more rigorous correlative adjustment analysis would reduce the net adjustment further. Cross presented a brief numerical illustration of this point, showing that under PPC's calculation, the appropriate correlative offset should be approximately $58–$64 million rather than the $42.65 million allowed by the examination team.
Appeals Officer Castañeda acknowledged the overlap issue and stated that the interaction between the CSA and royalty rate adjustments was "an important computational issue" that would need to be carefully addressed in any settlement. However, she did not indicate whether she would increase the correlative offset in her settlement analysis. This remains an open issue that will need to be addressed in the settlement negotiations.
V. Areas of Agreement
Based on the totality of the conference proceedings, Appeals Officer Castañeda appeared to agree or largely concede on the following points:
1. PBI Economic Substance. PBI had sufficient economic substance to participate in the CSA and to serve as IP owner and licensee for non-Americas territories. The IRS examination team's implicit economic substance challenge is unlikely to be a significant factor in the settlement. Castañeda's questions on this topic were thorough but did not suggest any fundamental disagreement with PPC's position, and her favorable comments indicated that she viewed PBI as a genuine operating entity rather than a shell.
2. IRC § 6662(e) Penalty. The IRC § 6662(e) substantial valuation misstatement penalty of $15.98 million should be abated. PPC's contemporaneous documentation and reasonable-cause defense were compelling, and Castañeda's statement that she was "inclined to not sustain the penalty" provides a clear indication of her intended resolution on this issue.
3. CUT Analysis Methodology. PPC's CUT analysis for the legacy IP royalty rate was methodologically sound and identified appropriate comparable license agreements. The IRS examination team's proposed 11.0% royalty rate was characterized by Castañeda as "well above" the interquartile range of PPC's comparable set, and she did not express any support for that rate. While Castañeda may seek a modest upward adjustment within the IQR, she appeared to accept the validity and reliability of Whitmore's CUT analysis.
4. PCT Valuation as Secondary Issue. The PCT valuation, while relevant as background context for the cost-sharing ratio analysis, was outside the examination years (2017–2020) and would not independently support a large adjustment for the years under examination. Castañeda treated this issue as secondary throughout the conference.
VI. Areas of Disagreement / Remaining Uncertainty
The following areas remain unresolved and may be the primary focus of settlement negotiations in the coming weeks:
1. CSA Cost-Sharing Percentages. While Castañeda was clearly skeptical of the examination team's proposed 8–12 percentage point increases to PBI's cost-sharing ratio, she did not concede that PPC's cost-sharing percentages were entirely correct. Her questions about new product launch projections, retrospective testing, and the RAB methodology suggest that she may seek a modest upward adjustment to PBI's cost-sharing percentages, potentially in the range of 1–3 percentage points above PPC's reported percentages. The magnitude of any such adjustment will be a key negotiating point.
2. Legacy IP Royalty Rate. Castañeda appeared to consider whether a royalty rate adjustment within the IQR of PPC's CUT analysis (above 4.5% but well below 11.0%) might be appropriate as a settlement position. Her question about whether a rate at the upper end of the IQR (6.8%) could be justified suggests she is exploring the range of potential settlement outcomes on this issue. Based on the tenor of her questions and comments, a settlement rate in the range of 5.0%–6.0% seems plausible. Any settlement rate within this range would represent a modest concession by PPC but would be substantially more favorable than the IRS's proposed 11.0% rate.
3. Correlative Offset Magnitude. The interaction between the CSA and royalty rate adjustments and the appropriate magnitude of the correlative offset under Treas. Reg. § 1.482-1(g) remains an open issue. Castañeda acknowledged the overlap but did not indicate her position on the appropriate offset calculation. This issue could have a meaningful impact on the net settlement amount.
4. Year-by-Year Allocation of Settlement Adjustment. Castañeda did not discuss the methodology for allocating any agreed-upon settlement adjustment across the four examination years (2017–2020). This will need to be addressed in the settlement negotiations, as the year-by-year allocation affects the computation of interest and potentially other considerations.
VII. Overall Assessment and Settlement Trajectory
The February 28, 2024 Appeals conference was constructive and professional throughout. Appeals Officer Castañeda was well-prepared, having thoroughly reviewed the full case file, the Formal Protest, the supporting exhibits, the examination team's RAR, and the IRS economist's analysis. Her questions were probing but fair, and she demonstrated a strong understanding of the transfer pricing issues at stake. The conference was conducted in a manner that was conducive to resolution, and Castañeda's demeanor and comments suggested that she is genuinely interested in achieving a reasonable settlement.
Based on Castañeda's reactions and questions throughout the conference, our assessment is that a settlement in the range of 10%–15% of the proposed $380.4 million net adjustment is achievable. This would translate to a settlement adjustment in the range of approximately $38.0 million to $57.1 million. This range is consistent with the settlement authority parameters established in the December 10, 2023 Settlement Authority Memorandum, which authorized a target settlement of 10%–15% of $380.4 million, with a hard ceiling of 20% (or approximately $76.1 million).
The specific factors supporting this assessment include:
• Castañeda's skepticism toward the examination team's 8–12 percentage point increases in the CSA cost-sharing ratio, which suggests she may seek only a modest (1–3 percentage point) adjustment;
• Castañeda's characterization of the IRS's proposed 11.0% royalty rate as "well above" PPC's IQR, suggesting a settlement rate significantly below 11.0% and likely in the range of 5.0%–6.0%;
• Castañeda's apparent acceptance of PBI's economic substance, which removes a significant potential basis for adjustment;
• Castañeda's strong indication that the $15.98 million penalty will be fully abated; and
• Castañeda's treatment of the PCT valuation as a secondary issue that would not independently drive a large adjustment.
The penalty appears very likely to be fully abated in any settlement, based on Castañeda's clear statement that she was "inclined to not sustain the penalty."
The overall financial outcome (tax, interest, and penalty) should be substantially favorable compared to the IRS's proposed assessment. The IRS's proposed assessment, if fully sustained, would result in a total liability of approximately $95.86 million (consisting of tax on the net adjustment of approximately $79.88 million plus the § 6662(e) penalty of $15.98 million, before interest). A settlement at 10%–15% of the proposed adjustment, with full penalty abatement, would result in a tax liability in the range of approximately $7.98 million to $11.97 million (before interest), representing a reduction of approximately 85%–90% from the IRS's proposed assessment.
Castañeda indicated at the conclusion of the conference that she would be in touch "within the next few weeks" with a written settlement proposal. The team should be prepared to analyze and respond promptly upon receipt of the proposal.
VIII. Supplemental Submission Requested
During the conference, Appeals Officer Castañeda requested that PPC provide supplemental information to assist her in completing her analysis. The specific items requested were:
1. Additional Comparable License Agreements. Castañeda asked PPC to identify any additional comparable license agreements that may have been entered into since the Whitmore CUT analysis was finalized, particularly any pharmaceutical license agreements from 2023 that had come to market and might be relevant to the arm's-length range for the legacy IP royalty rate.
2. Updated CPM/TNMM Benchmarking Data. Castañeda asked whether updated benchmarking data was available for the CPM/TNMM analysis, including any additional comparable company financial data that may have become available since the original analysis was prepared.
3. RAB Methodology Clarifications. Castañeda requested a brief written response to certain specific questions about the RAB methodology used to determine the CSA cost-sharing percentages, particularly relating to the methodology for projecting new product launches in non-Americas markets and the assumptions underlying those projections.
Cross agreed to provide this supplemental submission within 10 days of the conference, establishing a target date of March 8, 2024.
Simmons will coordinate with Dr. Helena Vasquez at Whitmore Valuation Group LLC to prepare the supplemental materials. The supplemental submission will include a cover letter from C&H, any updated comparable data identified by Whitmore, and a written response to Castañeda's RAB methodology questions. The submission will be reviewed by Cross and Hartwell prior to filing.
IX. Next Steps
The following action items should be completed in connection with the post-conference follow-up:
1. Supplemental Submission. Simmons and Dr. Vasquez to prepare and finalize the supplemental written submission to Appeals Officer Castañeda, addressing the three categories of supplemental information requested during the conference. Target submission date: March 8, 2024. Simmons to coordinate with Whitmore to begin the updated comparable search and CPM/TNMM data refresh immediately. Cross and Hartwell to review and approve the final submission before filing.
2. Client Debrief. Cross to debrief Marcus Whitfield (VP of Global Tax), Deborah Staines (General Counsel), and Rajesh Iyer on the conference results. The debrief will take the form of an email summary followed by a detailed follow-up call. Cross's debrief email is to go out today, March 1, 2024. The follow-up call should be scheduled within the next several business days to discuss the conference results in detail and to align on settlement strategy.
3. Settlement Preparation. Continue refining the sensitivity analysis of settlement ranges based on the insights gained from the conference. Simmons to update the settlement range model, incorporating the conference dynamics and Castañeda's apparent positions, with a focus on the 10%–15% target range. The model should include scenarios for varying CSA cost-sharing percentage adjustments (1–3 percentage points), royalty rate settlements (5.0%–6.0%), and correlative offset amounts, with computed tax and interest for each scenario.
4. Await Settlement Offer. Castañeda indicated that a written settlement proposal would follow "within the next few weeks." The team should be prepared to analyze and respond promptly upon receipt. Simmons to monitor for incoming correspondence from Appeals and to circulate any settlement proposal immediately upon receipt.
5. FIN 48 / ASC 740-10 Considerations. Following receipt of the settlement offer, the FIN 48 / ASC 740-10 uncertain tax position reserve analysis will need to be updated. PPC's current reserve stands at $62.4 million, which was established based on the full NOPA amount. The reserve will need to be adjusted downward if, as expected, the settlement is reached at a significantly lower amount. Simmons to coordinate with Martin Ogilvy at Crestfield & Associates LLP regarding the reserve recalculation, which will need to be completed in time for PPC's next quarterly financial reporting cycle.
6. Hargrove